JPMorgan Upgrades Alkermes (ALKS) to Overweight. PT $78
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder
October 20, 2016 4:00 PM EDTOnce-Daily ALKS 5461 Significantly Improved Depression Scores in Patients With Inadequate Response to Standard Antidepressant Therapies
Company to Request Meeting with FDA to Discuss Next Steps for Potential Regulatory Submission
Management to Hold Conference Call Today at 5:00 p.m. EDT
DUBLIN--(BUSINESS WIRE)-- Alkermes plc (NASDAQ: ALKS) today announced positive topline... More
